SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (29103)7/28/1999 4:34:00 PM
From: tuck  Respond to of 32384
 
Hi Henry,

Lake Ligand looks mighty attractive at these levels. Are you folks having a guess the earnings contest? Here's a benchmark if y'all are interested:

earningswhispers.com

Looking to buy in a few months. I just don't like the overall market right now, and am heading to cash and considering shorting unsound companies.

Cheers, Tuck



To: Henry Niman who wrote (29103)7/30/1999 4:28:00 PM
From: J Stone  Read Replies (2) | Respond to of 32384
 
Henry,

The WSJ reported on page 1 that "Tamoxifen loses effectiveness 2-5 years after patients begin taking it & may then actually start promoting cancer..." Could Targretin prevent this or at least extend Tamoxifen's effectiveness?

TIA

Jeff


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News